Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vaccine developments keep dollar down; Aussie and Kiwi strengthen

11/23/2020 | 03:57am EST

* Graphic: World FX rates in 2020 https://tmsnrt.rs/2RBWI5E

LONDON, Nov 23 (Reuters) - Progress towards a COVID-19 vaccine rollout lifted riskier currencies on Monday, keeping the dollar on its downward trend.

AstraZeneca said on Monday that its vaccine could be around 90% effective. The British drugmaker will prepare submission of data to authorities around the world that have a framework for conditional or early approval.

This was the latest in a string of positive vaccine developments after U.S.-based Moderna Inc said on Nov. 16 its experimental vaccine was 94.5% effective and, a week earlier, Pfizer Inc and Germany's BioNTech SE said their vaccine candidate had demonstrated greater than 90% efficacy that rose to 95% with analysis of full trial data.

In a quiet overnight session, in which price-action was limited by a holiday in Japan, currency market sentiment was also lifted by a top U.S. health official saying on Sunday that vaccinations could start taking place by mid-December.

"Markets are following pandemic news at the moment - vaccine optimism seems to be supporting risk assets for the time being," said Paul Donovan, chief economist at UBS Global Wealth Management in a note to clients.

The dollar, which dropped 0.4% last week, continued its downward trend as traders' risk appetite grew. It was down 0.1% versus a basket of currencies at 92.234 at 0813 GMT.

The dollar also lost out to the yen, with the pair changing hands at 103.76 at 0820 GMT.

The New Zealand dollar surged to a two-year high after strong retail sales data, reducing the risk of further policy easing. It was up 0.4% on the day at 0.6952 by 0822 GMT .

The Australian dollar - a liquid proxy for risk - was up 0.4% at 0.73285.

The euro edged up, at $1.1868. European Union leaders will continue to discuss the bloc's 1.8 trillion euro ($2.14 trillion) COVID-19 recovery plan, which has been vetoed by Poland and Hungary, German Chancellor Angela Merkel said last week.

Euro zone flash PMI data is due at 0900 GMT, followed by UK flash PMIs at 0930 GMT and U.S. at 1445 GMT.

ING strategists wrote in a note to clients that the data would have to be a significant surprise to have an adverse affect on the euro.

"Assuming the PMIs are not sharply weaker than consensus, we could see EUR/USD drifting up the 1.1915/20 area," they wrote.

German PMI data showed that the service sector in Europe's largest economy contracted faster this month after restrictive measures were introduced to slow the spread of the second wave of COVID-19.

The yuan slipped due to fresh U.S.-China tensions.

The Trump administration is close to declaring that 89 Chinese aerospace and other companies have military ties, restricting them from buying a range of U.S. goods and technology, according to a draft copy of the list seen by Reuters.

China said it opposed the possible move. The dollar was up around 0.2% against the offshore yuan at 0826 GMT, at 6.5651 . ($1 = 0.8425 euros) (Reporting by Elizabeth Howcroft, Editing by William Maclean)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.92% 7617 Delayed Quote.6.21%
AUSTRALIAN DOLLAR / CANADIAN DOLLAR (AUD/CAD) 0.02% 0.98088 Delayed Quote.0.60%
AUSTRALIAN DOLLAR / JAPANESE YEN (AUD/JPY) 0.13% 79.842 Delayed Quote.1.16%
AUSTRALIAN DOLLAR / NEW ZEALAND DOLLAR (AUD/NZD) -0.18% 1.06933 Delayed Quote.0.04%
AUSTRALIAN DOLLAR / SWISS FRANC (AUD/CHF) -0.13% 0.67994 Delayed Quote.0.90%
AUSTRALIAN DOLLAR / US DOLLAR (AUD/USD) -0.13% 0.76545 Delayed Quote.0.77%
BIONTECH SE -0.30% 107.3 Delayed Quote.29.99%
BRITISH POUND / AUSTRALIAN DOLLAR (GBP/AUD) 0.26% 1.79024 Delayed Quote.-0.19%
BRITISH POUND / JAPANESE YEN (GBP/JPY) 0.32% 142.936 Delayed Quote.0.88%
CANADIAN DOLLAR / JAPANESE YEN (CAD/JPY) 0.10% 81.387 Delayed Quote.0.62%
EURO / AUSTRALIAN DOLLAR (EUR/AUD) 0.32% 1.58508 Delayed Quote.-1.13%
EURO / JAPANESE YEN (EUR/JPY) 0.41% 126.565 Delayed Quote.0.02%
EURO / US DOLLAR (EUR/USD) 0.20% 1.21338 Delayed Quote.-0.92%
JAPANESE YEN / SWISS FRANC (JPY/CHF) -0.30% 0.8512 Delayed Quote.-0.18%
MODERNA, INC. 2.50% 158.75 Delayed Quote.49.07%
NEW ZEALAND DOLLAR / JAPANESE YEN (NZD/JPY) 0.29% 74.662 Delayed Quote.1.17%
PFIZER INC. -2.87% 36.005 Delayed Quote.-1.55%
UBS GROUP AG 0.54% 13.18 Delayed Quote.4.85%
UNITED STATES DOLLAR (B) / CHINESE YUAN IN HONG KONG (USD/CNH) -0.11% 6.4758 Delayed Quote.-0.36%
US DOLLAR / CHINESE YUAN RENMINBI (USD/CNY) -0.17% 6.459 Delayed Quote.-0.94%
US DOLLAR / JAPANESE YEN (USD/JPY) 0.23% 104.306 Delayed Quote.0.40%
All news about MODERNA, INC.
09:44aMARKET CHATTER : Moderna COVID-19 Vaccine Delivery Could Suffer Delays In Switze..
08:31aASTRAZENECA : Vaccine factory inspected amid EU dispute with AstraZeneca
07:28aEXCLUSIVE : Pharma distributors in talks with U.S. for cut of COVID-19 vaccine s..
06:03aRACING THE VIRUS : Why tweaking the vaccines won't be simple
04:50aMODERNA : Answering the Call
01/27Pfizer Covid-19 Vaccine Works Against Mutations Found in U.K, South Africa Va..
01/27EU Clashes With AstraZeneca Over Covid-19 Vaccine Shortfall
01/2747.2 MLN DOSES OF COVID-19 VACCINES : U.s. cdc
01/27EU health official blasts slow vaccine delivery, and is consulting with Canad..
01/27COVID SCIENCE-Drugs, vaccines less effective vs new virus variants; antibody ..
More news
Financials (USD)
Sales 2020 512 M - -
Net income 2020 -571 M - -
Net cash 2020 2 597 M - -
P/E ratio 2020 -127x
Yield 2020 -
Capitalization 61 624 M 61 624 M -
EV / Sales 2020 115x
EV / Sales 2021 5,41x
Nbr of Employees 1 100
Free-Float 90,0%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 137,93 $
Last Close Price 155,73 $
Spread / Highest target 18,8%
Spread / Average Target -11,4%
Spread / Lowest Target -55,7%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.49.07%61 624
LONZA GROUP AG3.66%49 275
CELLTRION, INC.-10.58%40 532
SEAGEN INC.-7.11%29 430